Prosecution Insights
Last updated: October 02, 2026

Examiner: BECKHARDT, LYNDSEY MARIE

Tech Center 3700 • Art Units: 1613 1615 1621 1674 3783

This examiner grants 28% of resolved cases

Analysis

Lyndsey Marie Beckhardt serves in Art Unit 1613 of Tech Center 3700. She has managed 568 resolved cases with an allowance rate of 27.8%. This 27.8% allowance rate provides a baseline for the probability of a grant on her docket. Practitioners can use this figure to evaluate the likelihood of success for applications in this technology area. The 568 resolved cases suggest a rigorous examination pattern for this examiner.

The interview lift is 48.0%. This metric indicates that cases with an interview have a significantly higher probability of allowance than those without an interview. When compared to the 27.8% allowance rate, the 48.0% lift suggests that direct communication is a critical factor in reaching a positive outcome. For the 568 resolved cases, interviews appear to be an exceptionally productive tactical choice. This 48.0% lift is a key indicator of examiner responsiveness.

The median days to allowance is 1456. This timeline represents the middle point of pendency for granted applications. Practitioners should expect a prosecution cycle around 1456 days. These metrics offer a data-grounded view of the examiner's procedural habits and the impact of interviews on the allowance rate. The 1456-day duration, combined with the interview lift, provides a set of benchmarks for navigating Art Unit 1613.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

27.8%
Allow Rate
-42.2% vs TC avg
658
Total Applications
+48.0%
Interview Lift
1456
Avg Prosecution Days
Based on 568 resolved cases, 2023–2026

Rejection Statute Breakdown

0.4%
§101 Eligibility
9.7%
§102 Novelty
47.6%
§103 Obviousness
23.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18327140 POWDER FOR ACHIEVING HEMOSTASIS Final Rejection Boston Scientific Scimed, Inc.
18727872 Antibacterial Resin and Molded Body Comprising Same Final Rejection LG Chem, Ltd.
17904553 CROSSLINKED POLY(LACTIDE-CO-GLYCOLIDE) (PLGA)-DIMETHACRYLATE COATINGS AND METHODS OF USE Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18012614 COLLAGEN-BIOGLASS ARTICLES AND METHODS OF MAKING THE SAME Non-Final OA Solventum Intellectual Properties Company
18099810 DELIVERY DEVICES AND METHODS FOR MAKING THE SAME Final Rejection THE REGENTS OF THE UNIVERSITY OF MICHIGAN
18727765 SKIN MICROBIOME FRIENDLY SUNSCREENS Non-Final OA BASF SE
18906741 Hair Treatment Compositions Having Anti-Dandruff Action Final Rejection Henkel AG & Co. KGaA
17785880 TINTING CONDITIONER HAVING IMPROVED DYEING PERFORMANCE Final Rejection Henkel AG & Co. KGaA
18408546 THERAPEUTIC AGENTS AND THEIR USE FOR TREATING CHRONIC WOUNDS Non-Final OA President and Fellows of Harvard College
17914134 METHODS FOR TISSUE REGENERATION AND KITS THEREFOR Final Rejection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
18157371 ANTI-FOULING IMPLANTABLE MATERIAL AND METHOD OF MAKING Non-Final OA Edwards Lifesciences Corporation
18044233 PHARMACEUTICAL COMPOSITION COMPRISING CHLOROQUINE AND USES THEREOF Non-Final OA Philip Morris Products S.A.
18401930 ANTI-POLLUTION ECO-FRIENDLY MATERIAL AND METHOD FOR PREPARING THE SAME Non-Final OA RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
17991937 Ionic Polymers For Medical Device Applications Final Rejection Becton, Dickinson and Company
18634454 FORMATION OF STABLE SUBMICRON PEPTIDE OR PROTEIN PARTICLES BY THIN FILM FREEZING Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18017583 COMPOSITION FOR PREVENTING ADHESION Non-Final OA The University of Tokyo
18722151 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN Non-Final OA L'OREAL
18716673 COMPOSITION COMPRISING A POLYHYDROXYALKANOATE COPOLYMER WITH A LONG HYDROCARBON-BASED CHAIN BEARING IONIC GROUP(S), AND METHOD FOR TREATING KERATIN MATERIALS USING THE COMPOSITION Non-Final OA L'Oreal
18704717 COMPOSITION COMPRISING A PARTICULAR OXIDATION DYE PRECURSOR AND TWO PARTICULAR ACIDS Non-Final OA L'OREAL
18726929 CMT-3 FORMULATIONS AND METHODS OF USING THE SAME Non-Final OA The Research Foundation for the State University of New York
18010653 DRUG-LOADED MEDICAL DEVICE AND PREPARATION METHOD, DRUG BALLOON, AND DRUG COATING PREPARATION METHOD Non-Final OA SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD.
18272705 PATCH COMPRISING SENSING COMPONENTS Non-Final OA ETH ZURICH
18577168 COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY Non-Final OA ASTRAZENECA PHARMACEUTICALS LP
17916215 NANOFIBER-ENABLED ENCAPSULATION DEVICES AND USES THEREOF Final Rejection CORNELL UNIVERSITY
17906433 IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF Final Rejection Takeda Pharmaceutical Company Limited
17273883 A MEDICAL TUBULAR DEVICE Non-Final OA BIOMODICS APS
16604173 SMECTITE SUSPENSION LIQUID COMPOSITION AND METHOD FOR PREPARING SAME Non-Final OA Liaoning Daewoong Pharmaceutical Co., Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month